Line 21: | Line 21: | ||
padding-top: 60px; | padding-top: 60px; | ||
z-index: 10; | z-index: 10; | ||
+ | display: none; | ||
} | } | ||
#sidebar a{ | #sidebar a{ | ||
Line 26: | Line 27: | ||
font-size: 16px; | font-size: 16px; | ||
} | } | ||
− | + | #sidebar img, | |
#sidebar .hovshow div{ | #sidebar .hovshow div{ | ||
display: none; | display: none; | ||
} | } | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
#sidebar .hovshow:hover{ | #sidebar .hovshow:hover{ | ||
display: inline-block; | display: inline-block; | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
} | } | ||
#sidebar .hovshow:hover div, | #sidebar .hovshow:hover div, | ||
#sidebar .hovshow div:hover{ | #sidebar .hovshow div:hover{ | ||
display: block; | display: block; | ||
− | |||
} | } | ||
− | @media screen and ( | + | @media screen and (min-width: 720px) { |
− | #sidebar{ | + | #sidebar .hovshow>a{ |
+ | white-space: nowrap; | ||
+ | overflow: hidden; | ||
+ | text-overflow:ellipsis; | ||
+ | } | ||
+ | #sidebar .hovshow:hover>a{ | ||
+ | white-space: normal; | ||
+ | text-overflow: clip; | ||
+ | clear: both; | ||
+ | border: 1px; | ||
+ | } | ||
+ | #sidebar .hovshow:hover{ | ||
+ | min-width: 225%; | ||
+ | } | ||
+ | #sidebar .hovshow:hover div, | ||
+ | #sidebar .hovshow div:hover{ | ||
+ | min-width: 125%; | ||
+ | } | ||
+ | |||
} | } | ||
− | |||
− | |||
/* 全局容器 */ | /* 全局容器 */ | ||
#ZB img, | #ZB img, | ||
Line 62: | Line 67: | ||
} | } | ||
#parCont>div{ | #parCont>div{ | ||
− | margin-top: | + | margin-top: 20px; |
+ | z-index: 2; | ||
} | } | ||
− | + | #ZB, | |
− | #ZB{ | + | #ZB p, |
+ | #ZB li, | ||
+ | #ZB h2, | ||
+ | #ZB h3, | ||
+ | #ZB h4, | ||
+ | #ZB h5{ | ||
color: #FAFAFA !important; | color: #FAFAFA !important; | ||
+ | font-weight: bold; | ||
+ | } | ||
+ | #ZB{ | ||
background-color: #303030; | background-color: #303030; | ||
− | + | margin-top: 60px; | |
overflow: auto; | overflow: auto; | ||
+ | height: calc(100vh -60px); | ||
} | } | ||
#ZB p{ | #ZB p{ | ||
Line 83: | Line 98: | ||
} | } | ||
#ZB h2{ | #ZB h2{ | ||
− | |||
padding: 20px 0px; | padding: 20px 0px; | ||
border-bottom: 1px solid white; | border-bottom: 1px solid white; | ||
} | } | ||
#ZB h3{ | #ZB h3{ | ||
− | |||
padding: 10px 0px; | padding: 10px 0px; | ||
font-family: Times New Roman; | font-family: Times New Roman; | ||
Line 97: | Line 110: | ||
} | } | ||
#ZB h5{/*图标注释*/ | #ZB h5{/*图标注释*/ | ||
− | |||
font-size: 16px; | font-size: 16px; | ||
text-align: center; | text-align: center; | ||
Line 103: | Line 115: | ||
margin: 10px auto; | margin: 10px auto; | ||
} | } | ||
− | |||
− | |||
− | |||
− | |||
/* 首页 */ | /* 首页 */ | ||
#LabStart{ | #LabStart{ | ||
display: -webkit-flex; | display: -webkit-flex; | ||
display: flex; | display: flex; | ||
+ | right: 0px; | ||
+ | top: 60px; | ||
justify-content: center; | justify-content: center; | ||
align-items: center; | align-items: center; | ||
+ | text-align: center; | ||
+ | position: fixed; | ||
+ | height: 100%; | ||
+ | z-index: 1; | ||
} | } | ||
#LabStart h1{ | #LabStart h1{ | ||
font-family: Arial Black; | font-family: Arial Black; | ||
− | color: | + | color:#404040; |
− | text-shadow: 5px 5px | + | text-shadow: 5px 5px 5px #808080; |
} | } | ||
− | + | @media screen and (max-width: 1000px) { | |
− | + | #LabStart h1{ font-size: 80px; } | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
} | } | ||
− | + | /*服务器*/ | |
#globalWrapper{ | #globalWrapper{ | ||
padding: 0px !important; | padding: 0px !important; | ||
} | } | ||
</style> | </style> | ||
+ | |||
+ | <div class="col-sm-12 fixed-top bg-dark" style="height: 60px; z-index: 10;"></div> | ||
+ | |||
+ | <!-- 移动端导航 --> | ||
+ | <button type="button" class="fixed-bottom btn btn-outline-light btn-dark rounded-circle d-md-none" id="mob">≣</button> | ||
<!-- 侧边栏 --> | <!-- 侧边栏 --> | ||
− | <div class="col-lg-2 col-md-3 bg-dark" id="sidebar"> | + | <div class="col-lg-2 col-md-3 bg-dark d-md-inline " id="sidebar"> |
− | < | + | <img class="rounded d-md-inline" src="https://static.igem.org/mediawiki/2019/d/de/T--CSU_CHINA--TimeLineS.jpg" alt="" > |
− | + | ||
− | + | ||
− | + | ||
− | + | <div class="list-group pt-1"> | |
− | + | <div class="hovshow" data-loc="#T1"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T0"> | |
− | + | <b>I</b>. Screening TNBC specific Transcription factors (TFs) | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T1P1"><b>Part I</b></a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T1P2"><b>Part II</b></a> | |
− | + | ||
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T2"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T1"> | |
− | + | <b>II</b>. Screening of miRNA which are low expressed in TNBC | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T2P1"><b>Part I</b>: qPCR for confirming the low expressed miRNA</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T2P2"><b>Part II</b>: qPCR for confirming the high expressed but specific miRNA</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T3"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T2"> | |
− | + | <b>III</b>. Design and test of miRNA Binding Site (miR-BS) | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T3P1"><b>Part I</b>: Construction of miR-BS plasmid</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T3P2"><b>Part II</b>: Gauging the efficiency of miR-BS: miRNA mimics assey</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T4"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T3"> | |
− | + | <b>IV</b>. Design and test of Sponge | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T4P1"><b>Part I</b>: Sponge Design</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T4P2"><b>Part II</b>: the primer of Sponge and PCR amplification</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T4P3"><b>Part III</b>: Gauge the efficiency of expression of the Sponge</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T4P4"><b>Part IV</b>: Luciferase assay</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T5"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T4"> | |
− | + | <b>V</b>. Synthetic Promoter | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T5P1"><b>Part I</b>: Design of s(ESR1)p</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T5P2"><b>Part II</b>: Design of s(GATA3)p</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T5P3"><b>Part III</b>: Design of G8p</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T5P4"><b>Part IV</b>: Primer design</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T5P5"><b>Part V</b>: construction of synthetic promoter</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T5P6"><b>Part VI</b>: Test of promoter</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T6"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T5"> | |
− | + | <b>VI</b>. Golden gate | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T6P1"><b>Part I</b>: Basic Plasmid</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T6P2"><b>Part II</b>: Modified design of Module1</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T6P3"><b>Part III</b>: Modified design of Module2</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T6P4"><b>Part IV</b>: Result of constructing of Plasmid and important elements</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T7"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T6"> | |
− | + | <b>VII</b>. Construction of Module1 | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T7P1"><b>Part I</b>: construction of pLN431-s(GATA3)p-GAD-miR101-BS</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T7P2"><b>Part II</b>: Amplification of plasmid connected and sending to sequence</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T8"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T7"> | |
− | + | <b>VIII</b>. Design of Module2 | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T8P1"><b>Part I</b>: Primers with enzyme recognition site</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T8P2"><b>Part II</b>: Construction of pEGFP-N1-s(ESR1)p-Sponge</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T8P3"><b>Part III</b>: the structure of Module2 after Golden gate connecting</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T8P4"><b>Part IV</b>: Amplification of plasmid connected and sending to sequence</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#T9"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#T8"> | |
− | + | <b>IX</b>. Design of Module3 | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T9P1"><b>Part I</b>: sequence of primers</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T9P2"><b>Part II</b>: G8p Plasmid construction </a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#T9P3"><b>Part III</b>:Test when Module1+Module3 to examine whether G8p can express</a> | |
</div> | </div> | ||
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#TA"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#TA"> | |
− | + | <b>X</b>. DAPI Staining for final test whether the whole system can work | |
− | + | </a> | |
− | + | </div> | |
− | + | <div class="hovshow" data-loc="#TB"> | |
− | + | <a class="list-group-item list-group-item-action bg-dark text-white p-1" href="#TB"> | |
− | + | <b>XI</b>. Transferrin | |
− | + | </a> | |
− | + | <div class="list-group"> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#TBP1"><b>Part I</b>: Transferrin-TFR binding motif</a> | |
− | + | <a class="list-group-item list-group-item-action text-dark p-1" data-loc="#TBP2"><b>Part II</b>: microscope observation</a> | |
</div> | </div> | ||
</div> | </div> | ||
− | < | + | </div> |
+ | |||
+ | <div class="btn-group w-100 mt-1 mb-5"> | ||
+ | <button type="button" class="btn btn-info" id="pre">previous Task</button> | ||
+ | <button type="button" class="btn btn-info" id="next">next Task</button> | ||
+ | </div> | ||
</div> | </div> | ||
+ | <!-- 首页 --> | ||
+ | <div class="col-lg-10 col-md-9" id="LabStart"> | ||
+ | <h1 class="display-1">LAB TASKS</h1> | ||
+ | </div> | ||
+ | <script>$("#LabStart").height($(document).height()-60);</script> | ||
+ | |||
<script>$("#globalWrapper").height($(document).height());</script> | <script>$("#globalWrapper").height($(document).height());</script> | ||
− | <div class="col-lg-10 offset-lg-2 col-md-9 offset-md-3" id="ZB"> | + | <div class="col-lg-10 offset-lg-2 col-md-9 offset-md-3" id="ZB"> |
<script>$("#ZB").height($(document).height()-60);</script> | <script>$("#ZB").height($(document).height()-60);</script> | ||
<div class="row" id="parCont"> | <div class="row" id="parCont"> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
<!-- 导航 --> | <!-- 导航 --> | ||
− | <div class="col-md- | + | <div class="col-md-10 offset-md-1" id="navfig"> |
+ | <img src="https://static.igem.org/mediawiki/2019/d/de/T--CSU_CHINA--TimeLineS.jpg" alt=""> | ||
</div> | </div> | ||
− | <script>$("#navfig").height($(document).height()- | + | <script>$("#navfig").height($(document).height()-80);</script> |
<!-- 1 fig*3 --> | <!-- 1 fig*3 --> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T1"> |
<h2>Task One: Screening TNBC specific Transcription factors (TFs)</h2> | <h2>Task One: Screening TNBC specific Transcription factors (TFs)</h2> | ||
<h3>May 13-25</h3> | <h3>May 13-25</h3> | ||
Line 299: | Line 315: | ||
</table> | </table> | ||
</div> | </div> | ||
− | |||
<h5>Tab.2: Six TFs we choose to examine further:<span>E2F1/FOXM1/FOXA1/PITX1/PTTG1/GATA3</span></h5> | <h5>Tab.2: Six TFs we choose to examine further:<span>E2F1/FOXM1/FOXA1/PITX1/PTTG1/GATA3</span></h5> | ||
<table class="table table-sm table-inverse table-responsive table-secondary table-striped"> | <table class="table table-sm table-inverse table-responsive table-secondary table-striped"> | ||
Line 483: | Line 498: | ||
<!-- 2 fig*3--> | <!-- 2 fig*3--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T2"> |
<h2>Task Two: Screening of miRNA specifically expressed in TNBC</h2> | <h2>Task Two: Screening of miRNA specifically expressed in TNBC</h2> | ||
<h3>May27-29</h3> | <h3>May27-29</h3> | ||
Line 508: | Line 523: | ||
<!-- 3 fig*3--> | <!-- 3 fig*3--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T3"> |
<h2>Task Three: Design and test of miRNA Binding Site (miR-BS)</h2> | <h2>Task Three: Design and test of miRNA Binding Site (miR-BS)</h2> | ||
<h3>June 3-10</h3> | <h3>June 3-10</h3> | ||
Line 561: | Line 576: | ||
<!-- 4 fig*2--> | <!-- 4 fig*2--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T4"> |
<h2>Task Four: Design and test of Sponge</h2> | <h2>Task Four: Design and test of Sponge</h2> | ||
<h3>July 13-24</h3> | <h3>July 13-24</h3> | ||
Line 612: | Line 627: | ||
<!-- 5 fig*5--> | <!-- 5 fig*5--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T5"> |
<h2>Task Five: Synthetic Promoter</h2> | <h2>Task Five: Synthetic Promoter</h2> | ||
<h3>July 25-30</h3> | <h3>July 25-30</h3> | ||
Line 688: | Line 703: | ||
<!-- 6 fig*13--> | <!-- 6 fig*13--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T6"> |
<h2>Task Six: Golden gate</h2> | <h2>Task Six: Golden gate</h2> | ||
<h3>August 6-20</h3> | <h3>August 6-20</h3> | ||
Line 700: | Line 715: | ||
<h3 id="T6P2">Part II: Modified design of Module1</h3> | <h3 id="T6P2">Part II: Modified design of Module1</h3> | ||
<p>The recognition site and cutting site of BsmBI in Module1</p> | <p>The recognition site and cutting site of BsmBI in Module1</p> | ||
− | <img src="https://static.igem.org/mediawiki/2019/d/d3/T--CSU_CHINA--LabT6P2F6.2.1.jpg" alt=""> | + | <div class="col-md-10 offset-md-1"> |
− | + | <img src="https://static.igem.org/mediawiki/2019/d/d3/T--CSU_CHINA--LabT6P2F6.2.1.jpg" alt=""> | |
+ | <img src="https://static.igem.org/mediawiki/2019/5/55/T--CSU_CHINA--LabT6P2F6.2.2.png" alt=""> | ||
+ | </div> | ||
<h3 id="T6P3">Part III: Modified design of Module2</h3> | <h3 id="T6P3">Part III: Modified design of Module2</h3> | ||
Line 738: | Line 755: | ||
<!-- 7 fig*3--> | <!-- 7 fig*3--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T7"> |
<h2>Task Seven: Construction of Module1</h2> | <h2>Task Seven: Construction of Module1</h2> | ||
<h3>August 24-30</h3> | <h3>August 24-30</h3> | ||
Line 766: | Line 783: | ||
<!-- 8 fig*4--> | <!-- 8 fig*4--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T8"> |
<h2>Task Eight: Design of Module2</h2> | <h2>Task Eight: Design of Module2</h2> | ||
<h3>September 13-20</h3> | <h3>September 13-20</h3> | ||
Line 892: | Line 909: | ||
<!-- 9 fig*5--> | <!-- 9 fig*5--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="T9"> |
<h2>Task Nine: Design of Module3</h2> | <h2>Task Nine: Design of Module3</h2> | ||
<h3>September 2-11</h3> | <h3>September 2-11</h3> | ||
Line 941: | Line 958: | ||
<!-- 10 fig*1--> | <!-- 10 fig*1--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="TA"> |
<h2 id="TA">Task Ten: DAPI Staining for final test whether the whole system can work</h2> | <h2 id="TA">Task Ten: DAPI Staining for final test whether the whole system can work</h2> | ||
<h3>October 8-11</h3> | <h3>October 8-11</h3> | ||
Line 951: | Line 968: | ||
<!-- 11 fig*9--> | <!-- 11 fig*9--> | ||
− | <div class="col-md-12"> | + | <div class="col-md-12" id="TB"> |
<h2>Task Eleven: Transferrin</h2> | <h2>Task Eleven: Transferrin</h2> | ||
<h3>September 21-29</h3> | <h3>September 21-29</h3> | ||
<h3 id="TBP1">Part I Transferrin-TFR binding motif</h3> | <h3 id="TBP1">Part I Transferrin-TFR binding motif</h3> | ||
− | <div class="col-md- | + | <div class="col-md-8 offset-md-2"> |
<img src="https://static.igem.org/mediawiki/2019/6/6f/T--CSU_CHINA--LabT11P1F11.1.1.jpg" alt=""> | <img src="https://static.igem.org/mediawiki/2019/6/6f/T--CSU_CHINA--LabT11P1F11.1.1.jpg" alt=""> | ||
</div> | </div> | ||
Line 983: | Line 1,000: | ||
</div> | </div> | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
</div> | </div> | ||
</div> | </div> | ||
Line 993: | Line 1,007: | ||
<script> | <script> | ||
$("#navbar_LAB").addClass("active"); | $("#navbar_LAB").addClass("active"); | ||
+ | //前一个task | ||
+ | $("#pre").click(function(){ | ||
+ | if($("#parCont div:visible:first").length == 0) | ||
+ | $(".hovshow:last > a:first").click(); | ||
+ | else $("#parCont div:visible:first").hide().prev("div").show(); | ||
+ | $("#ZB").scrollTop(0); | ||
+ | }); | ||
+ | //后一个task | ||
+ | $("#next").click(function(){ | ||
+ | if($("#parCont div:visible:first").length == 0) | ||
+ | $(".hovshow:first > a:last").click(); | ||
+ | else $("#parCont div:visible:first").hide().next("div").show().scrollTop(0); | ||
+ | $("#ZB").scrollTop(0); | ||
+ | }); | ||
+ | //跳转滚动效果 | ||
+ | $("#sidebar a").click(function(){ | ||
+ | $("#parCont").children().hide(); | ||
+ | var plink = $(this).parents(".hovshow").data("loc"); //显示TASK | ||
+ | $(plink).show(); | ||
+ | window.location.href = plink; | ||
+ | var target= $($(this).data("loc")).offset().top - 50;//滚动至part | ||
+ | setTimeout(function(){ | ||
+ | $("#ZB").animate({scrollTop:target}, 500); | ||
+ | },500); | ||
+ | }); | ||
+ | $(document).ready(function(){ | ||
+ | $("#mob").click(function(){ | ||
+ | $("#sidebar").toggle(); | ||
+ | }); | ||
+ | $("#parCont").children().hide(); | ||
+ | //导航 | ||
+ | $("#sidebar img").click(function(){ | ||
+ | $("#navfig").toggle(); | ||
+ | }); | ||
+ | //加载 | ||
+ | setTimeout(function(){ | ||
+ | $("#labLoad").hide(); | ||
+ | }, 800) | ||
+ | }); | ||
</script> | </script> | ||
Revision as of 16:08, 16 November 2019
loading……
LAB TASKS
Task One: Screening TNBC specific Transcription factors (TFs)
May 13-25
We get our idea that we can design synthetic promoters to initiate every Modules by receiving the activation of the TFs specifically expressed in human Triple Negative Breast Cancer (TNBC) cell lines, then we utilize Bioinformatics methods to screen TFs specifically low expressed in TNBC
Part I
We utilize R (Ver. 3.0.2) to analyze the data from The Cancer Genome Atlas (TCGA) database and turn to GEPIA database to find the differentially expressed TF in TNBC cells.
Then, we consider ESR1 as the best choice and six TFs (E2F1/FOXM1/FOXA1/PITX1/PTTG1/GATA3) for further examination.
Tab.1: Best choice we screen——ESR1
TOP10 GEPIA TCGA Better choice |
Gene Symbol | Gene ID | Median (Tumor) | Median (Tumor) | Log2(Fold Change) | Percentage |
ESR1 | ENSG00000091831.21 | 389.397 | 78.58 | 2.294 | 1 |
Tab.2: Six TFs we choose to examine further:E2F1/FOXM1/FOXA1/PITX1/PTTG1/GATA3
TCGA | GEPIA ANOVA | GEPIA LIMMA | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GENE | logFC | logCPM | PValue | FDR | GENE | FC | P | ID | TUMOR | NORMAL | GENE | FC | P | ID | TUMOR | NORMAL |
ESR1 | 1.665440871 | 8.646033307 | 9.29926E-11 | 3.12438E-10 | ESR1 | 2.636 | 7.79E-13 | ENSG00000091831.21 | 70.238 | 10.46 | ESR1 | 2.636 | 4.11E-23 | ENSG00000091831.21 | 70.238 | 10.46 |
E2F1 | 2.833464601 | 4.378812917 | 1.40214E-64 | 6.6219E-63 | E2F1 | 2.048 | 9.15E-130 | ENSG00000101412.12 | 9.09 | 1.44 | E2F1 | 2.048 | 1.12E-171 | ENSG00000101412.12 | 9.09 | 1.44 |
FOXM1 | 3.633398105 | 5.396014721 | 1.31517E-68 | 7.15612E-67 | FOXM1 | 2.902 | 1.34E-160 | ENSG00000111206.12 | 17.09 | 1.42 | FOXM1 | 2.902 | 2.19E-207 | ENSG00000111206.12 | 17.09 | 1.42 |
PITX1 | 4.362142066 | 4.915013805 | 1.64223E-57 | 5.87336E-56 | PITX1 | 3.49 | 5.14E-119 | ENSG00000069011.15 | 14.73 | 0.4 | PITX1 | 3.49 | 3.25E-173 | ENSG00000069011.15 | 14.73 | 0.4 |
PTTG1 | 3.383676082 | 4.430763315 | 3.09255E-78 | 2.48664E-76 | PTTG1 | 3.255 | 3.08E-208 | ENSG00000164611.12 | 40.229 | 3.32 | PTTG1 | 3.255 | 2.51E-277 | ENSG00000164611.12 | 40.229 | 3.32 |
FOXA1 | 1.89165353 | 7.877360438 | 5.0635E-16 | 2.49821E-15 | FOXA1 | 2.934 | 1.03E-31 | ENSG00000129514.5 | 158.253 | 19.84 | FOXA1 | 2.934 | 1.04E-58 | ENSG00000129514.5 | 158.253 | 19.84 |
GATA3-AS1 | 2.53227903 | 2.954932901 | 7.62061E-20 | 4.79732E-19 | GATA3 | 2.399 | 3.75E-31 | ENSG00000107485.15 | 251.793 | 46.921 | GATA3 | 2.399 | 8.08E-63 | ENSG00000107485.15 | 251.793 | 46.921 |
Part II
Through examinations, we choose ESR1 and GATA3 to activate the synthetic promotor for Module 1 and Module 2.
Fig.1: the expression of FOXM1、PTTG1、FOXA1、PITX1 in NC/Tumor lines
Fig.2: the expression of E2F1、GATA3 in NC/Tumor lines
Fig.3: the expression of ESR1 in NC/Tumor lines
Results: According to Fig.1-3, we observe that ESR1 and GATA3 are better differentially expressed TFs between TNBC cells and normal cells, so we utilize ESR1 to activate the synthetic promoter of Module1, and GATA3 of Module2.
Task Two: Screening of miRNA specifically expressed in TNBC
May27-29
According to articles and databases, we choose series of miRNA to examine which are specifically expressed in TNBC
Part I: qPCR for confirming the low expressed miRNA
Through miRNA reverse transcription reaction, we get the cDNA of miRNA and utilize the cDNA to examine the expression via qPCR.
Fig.1: the expression of 12 miRNAs.
Observing the result of qPCR (as Fig.1 showed), we notice that miR-146 and miR-101 are better choices for their low expression in MDA-MB-231 cells comparing to normal cells like HBL-100.
Part II: qPCR for confirming the high expressed but specific miRNA
We notice that some miRNA are specifically high expressed comparing to normal cells, which can be the substrates of their Sponge to lower their expression so that they can be the trigger specifically in TNBC cells. We focused on two miRNA: miR-148b and miR-141, Then we examined their expression, the result was showed as Fig.2.
Fig.2: the specific expression of miR-148b and miR-141;(left)HBL-100,(Right)MDA-MB-231
miR-148b and miR-141 are much higher expressed in TNBC cells comparing to normal cells. Then we can design their Sponge to bind them and lower the expression so as to trigger the initiation of Module1
Result: We finally choose miR-101, miR-146 and so on as low-expressed miRNA specifically in TNBC. Also, we choose miR-141 and miR-148b for the specifically high expression in TNBC cells and modify them for the substrates of Sponge.
Task Three: Design and test of miRNA Binding Site (miR-BS)
June 3-10
Part I: Construction of miR-BS plasmid
Plasmid: LSBr5and3
- the copy of the whole sequence of miR-BS(Tab.1)
- PCR of miR-BS
- Double Digestion on plasmid and miR-BS
- Connection of plasmid and miR-BS
- Translate them to E.coli cells
Fig.3.1.1 the structure of miR-141-BS
Fig.3.1.2 the structure of miR-148b-BS
Tab.3.1.11: the complete sequence of miR-BS
Items | Sequence (5’→3’) | Length |
---|---|---|
miR-141-BS | ATTGTGACTAGACCATTTCTAATGCCATTGTGACTAGACCATTTCTAATGCCATTGTGACTAGACCATTTCTAATGCCATTGTGACTAGACCATTTCTAATGGCAA | 106 |
miR-148b-BS | ACAAAGTTCTGTGATGCACTGAATGCCACAAAGTTCTGTGATGCACTGAATGCCACAAAGTTCTGTGATGCACTGAATGCCACAAAGTTCTGTGATGCACTGAATGGCAA | 110 |
Part II: Gauging the efficiency of miR-BS: miRNA mimics assey
- Put miRNA mimics to the E.coli cell medium
- The report genes on the plasmid will make cell take on different colors since the binding of miR-BS and miRNA after inserting the sequence of miR-BS to the region of mKate2 (transfected unsuccessfully: mKate2+mCherry can express together while transfected successfully, only mCherry can express)
- FACS gauging, we can get the efficiency of miR-BS by the rate of different colors of cell groups
Fig.3.2.1 the structure of plasmid LSBr5and3
Task Four: Design and test of Sponge
July 13-24
Part I: Sponge Design
Fig 4.1.1: the sequence of Sponge-miR141
Fig 4.1.2: the sequence of Sponge-miR148-b
Part II: the primer of Sponge and PCR amplification
Tab.4.2.1 the sequences or the primers of miR-Sponge
Items | Sequence(5’→3’) |
---|---|
F-miR-141-sponge | CGTCTCCAGCCGTAGAAGGA |
R-miR-141-sponge | CGTCTCCCGAGCATCTTCCT |
F-miR-148b-sponge | CGTCTCCAGCCACAAAGTTG |
R-miR-148b-sponge | CGTCTCCCGAGTCAGTGCAT |
Part III: Gauge the efficiency of expression of the Sponge
Plasmid: pEGFP-N1-sponge141_148b
We transfect the sequence of sponge into the plasmid. 24 hours after transfection, observe the results and record the expression of fluorescent protein.
Part IV : Luciferase assay
We use luciferase reporter assay kits comprising expression vectors that contain the luciferase reporter gene. To perform the reporter assay, we clone the sponge sequence upstream of the luciferase gene in the vectors then introduce that resulting vector DNA into cells, and let the cells grow for a period of time. We then collect the cells, break them open to release all the proteins (including the luciferase), add luciferin and all the necessary cofactors, and measure the enzymatic activity using a luminometer. The luciferase activity can be directly correlated with the activity of the sponge.
Task Five: Synthetic Promoter
July 25-30
Part I: Design of s(ESR1)p
Plasmid: pGL4.22-s(ESR1)p
Fig5.1.1: the structure of s(ESR1)p
Part II: Design of s(GATA3)p
Plasmid: pGL4.22-s(GATA3)p
Fig5.2.1 the structure of s(GATA3)p
Part III: Design of G8p
Plasmid: pGL4.22-G8p
Fig5.3.1 the structure of G8p
Part IV: Primer design
Tab.5.4.1 The list of primer of promoter for PCR
F-ESR1-EcoRI | CCGGAATTCATGACCATGACCCTCCAC |
R-ESR1-BamHI | CGCGGATCCTCAGACCGTGGCAGGGAA |
F-GATA3-EcoRI | CCGGAATTCATGGAGGTGACGGCGGAC |
R-GATA3-BamHI | CGCGGATCCCTAACCCATGGCGGTGAC |
R-G8p-XhoI | CCGCTCGAGTTTACCAACAGTACCGGA |
R-lateADEp-XhoI | CCGCTCGAGAGAGTGAGGACGAACGCC |
F-G8p-SacI | CGAGCTCCGATAGGTACCGAGTTTC |
F-G8p-KpnI | CGGGGTACCCGATAGGTACCGAGTTTC |
Part V: construction of synthetic promoter
We use the JASPER to get the TF binding sites (TF-BSs), and add different spacers between the tandem repeats of TF-BSs to avoid creating new binding sites in order to ensure the specificity.
Part VI: Test of promoter
1.Protomer selection
2.efficiency test
Task Six: Golden gate
August 6-20
Aiming at connecting Module1 with Module2, we utilize Golden gate method.
Part I: Basic Plasmid
Plasmid: pEGFP-N1-lacZ
Fig.6.1.1 the sequence of BsmBI-lacZp+lacZ-BsmBI
Part II: Modified design of Module1
The recognition site and cutting site of BsmBI in Module1
Part III: Modified design of Module2
1.Basic Vector: pEGFP-N1-lacZ
2.Promoter region: BsmBI RS-s(ESR1)p-BsmBI RS
3.screening and identification region: BsmBI RS-lacZp-lacZ-BsmBI RS
4.Final construction
The recognition site and cutting site of BsmBI in Module2
4.1 pEGFP-N1-Module2(148b): pEGFP-N1-s(ESR1)p-(Sponge-148b)-(miR-148b-BS)
4.2 pEGFP-N1-Module2(141): pEGFP-N1-s(ESR1)p-(Sponge-141)-(miR-141-BS)
Fig.6.3 the structure of Sponge-miR141 with BsmBI Recognition Site
Part IV: Result of construction of plasmid and important elements
Task Seven: Construction of Module1
August 24-30
Part I: construction of pLN431-s(GATA3)p-GAD-miR101-BS
- the basic plasmid:pLN431
- the promoter s(GATA3)p
- the synthetic TF: GAD——GALBD+ VP16 AD
- the binding site of miRNA: miR-101-BS
- the Golden gate connection
Fig.7.1 the process of golden gate connection for the whole Module1
Fig7.2 the whole structure of Module1 after connecting
Fig 7.3 the structure of GAD
Part II
Amplify the plasmid connected and send to sequence.
Task Eight: Design of Module2
September 13-20
Part I: Primers with enzyme recognition site
Tab.1 sequence of primers
F-s(ESR1)p-BsmBI | GCCATCGTCTCCACTGAGGTCACGGTGACCTTCT |
R-s(ESR1)p-BsmBI | CGATTCGTCTCCGGCTAGAGTGAGGACGAA |
F-miR141spe-EcoRI | CCGGAATTCGCCGTAGAAGGAATGTCA |
R-miR141spe-BamHI | CGCGGATCCGAGCATCTTCCTTACAGT |
F-miR148bspe-EcoRI | CCGGAATTCGCCACAAAGTTGTGAAAT |
R-miR148bspe-BamHI | CGCGGATCCGAGTCAGTGCATTTCACA |
F-s(ESR1)p-KpnI | GGGGTACCAGGTCACGGTGACCTTCT |
Part II: Construction of pEGFP-N1-s(ESR1)p-Sponge
1. Elements and connection
1.1 Sponge of miR-141 and miR-148b
Tab.8.2 Sequence of miR-sponge with BsmBI recognition site
Items | Sequence ( 5’→3’) | Length |
---|---|---|
Sponge-141-BsmBI | CGTCTCCAGCCGTAGAAGGAATGTCACAACCAGATAGACCAACACTGTAAGGAAGATGGATAGGTAGAAGGAATGTCACAACCAGATAGACCAACACTGTAAGGAAGATGGATAGGTAGAAGGAATGTCACAACCAGATAGACCAACACTGTAAGGAAGATGGATAGGTAGAAGGAATGTCACAACCAGATAGACCAACACTGTAAGGAAGATGCTCGGGAGACG | 225 |
Sponge-148b-BsmBI | CGTCTCCAGCCACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTAGACAAAGTTGTGAAATGCACTGACTCGGGAGACG | 226 |
1.2 basic vector: pEGFP-N1
Fig.8.2.1 the structure of vector
1.3 Promoter: s(ESR1)p
1.4 Connection: Golden gate method
Vector | 2μl |
miR-Sponge(miR-101;141;148b) | 1μl |
s(ESR1)p | 1μl |
10XT4 Ligase Buffer | 2μl |
10XBuffer | 2μl |
BsmBI | 1μl |
ddH2O | 11μl |
Total | 20μl |
Part III: the structure of Module2 after Golden gate connecting
Part IV
Amplify the plasmid connected and send to sequence.
Task Nine: Design of Module3
September 2-11
Part I: sequence of primers
R-G8p-XhoI | CCGCTCGAGTTTACCAACAGTACCGGA |
R-lateADEp-XhoI | CCGCTCGAGAGAGTGAGGACGAACGCC |
F-G8p-SacI | CGAGCTCCGATAGGTACCGAGTTTC |
F-G8p-KpnI | CGGGGTACCCGATAGGTACCGAGTTTC |
Part II: G8p Plasmid construction
Structure: pLN431-G8p-yCD-(miR-BS)
Fig,9.2.1 the structure of pLN431
Fig.9.2.2 the structure of G8p
Fig.9.2.3 the structure of yCD
Part III:Test when Module1+Module3 to examine whether G8p can express
Task Ten: DAPI Staining for final test whether the whole system can work
October 8-11
Comparing Day2 and Day3, we notice that the whole system transfected into MDA-MB-231 cells work successfully and kill TNBC cells efficiently and specifically.